DSS, Inc. Reports 32% Revenue Decline and Increased Losses in Q2 2026

DSS, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenue falling to $3.6 million, a decrease of 32% compared to $5.3 million in the same period of 2025. For the first half of 2026, revenue was $7.9 million, down 22% from $10.2 million in the prior year. The decline was attributed to reduced customer orders and delays in onboarding new clients, particularly in the Printed Products segment, which saw a 24% drop in revenue. The company also experienced substantial decreases in its Securities and Commercial Lending segments, with revenues down 66% and 63%, respectively.

DSS's total costs and expenses decreased by 15% to $7.4 million for the second quarter, compared to $8.7 million in 2025. The cost of revenue for Printed Products fell by 18%, reflecting the overall decline in sales. However, the company reported an operating loss of $3.8 million for the quarter, compared to a loss of $3.4 million in the same period last year. The net loss attributable to common stockholders was $4.8 million, a 123% increase from the previous year's loss of $2.2 million.

In terms of strategic developments, DSS has been focusing on its four business lines: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. The company is also in the process of transitioning its Commercial Lending operations to focus more on inventory and equipment loans. Additionally, DSS has been actively managing its expenses, resulting in a 36% reduction in sales, general, and administrative compensation costs for the first half of 2026.

Operationally, DSS reported a decrease in customer engagement metrics, with a notable drop in user statistics across its segments. The company’s cash position as of June 30, 2026, was approximately $4.1 million, down from $6.2 million at the end of 2025. DSS also reported negative working capital of $39.9 million, raising concerns about its ability to continue as a going concern. The company plans to pursue additional liquidity through asset sales and financing activities while continuing to reduce operating expenses.

Looking ahead, DSS management remains cautious about the company's financial outlook, emphasizing the need for strategic adjustments to improve performance. The company is exploring opportunities for geographic expansion and product adoption, particularly in its Biotechnology segment, which aims to address urgent medical needs. However, the ongoing challenges in revenue generation and the substantial losses reported raise significant uncertainty regarding the company's future viability.